Logo image of AQST

AQUESTIVE THERAPEUTICS INC (AQST) Stock Fundamental Analysis

NASDAQ:AQST - US03843E1047 - Common Stock

3.9 USD
+0.04 (+1.04%)
Last: 8/26/2025, 8:15:13 PM
3.8703 USD
-0.03 (-0.76%)
After Hours: 8/26/2025, 8:15:13 PM
Fundamental Rating

2

Overall AQST gets a fundamental rating of 2 out of 10. We evaluated AQST against 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of AQST have multiple concerns. AQST is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AQST has reported negative net income.
AQST had a negative operating cash flow in the past year.
AQST had negative earnings in each of the past 5 years.
In the past 5 years AQST always reported negative operating cash flow.
AQST Yearly Net Income VS EBIT VS OCF VS FCFAQST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

AQST has a worse Return On Assets (-69.42%) than 66.84% of its industry peers.
Industry RankSector Rank
ROA -69.42%
ROE N/A
ROIC N/A
ROA(3y)-50.85%
ROA(5y)-71.01%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AQST Yearly ROA, ROE, ROICAQST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

AQST has a better Gross Margin (61.09%) than 69.43% of its industry peers.
AQST's Gross Margin has improved in the last couple of years.
AQST does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.09%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y2.38%
AQST Yearly Profit, Operating, Gross MarginsAQST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

3

2. Health

2.1 Basic Checks

AQST does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AQST has more shares outstanding
The number of shares outstanding for AQST has been increased compared to 5 years ago.
AQST has a better debt/assets ratio than last year.
AQST Yearly Shares OutstandingAQST Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AQST Yearly Total Debt VS Total AssetsAQST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -4.91, we must say that AQST is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of AQST (-4.91) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.91
ROIC/WACCN/A
WACC10.78%
AQST Yearly LT Debt VS Equity VS FCFAQST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

AQST has a Current Ratio of 3.53. This indicates that AQST is financially healthy and has no problem in meeting its short term obligations.
AQST's Current ratio of 3.53 is fine compared to the rest of the industry. AQST outperforms 60.10% of its industry peers.
A Quick Ratio of 3.18 indicates that AQST has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.18, AQST is in the better half of the industry, outperforming 60.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.53
Quick Ratio 3.18
AQST Yearly Current Assets VS Current LiabilitesAQST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

AQST shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -105.88%.
AQST shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -24.38%.
Measured over the past years, AQST shows a small growth in Revenue. The Revenue has been growing by 1.82% on average per year.
EPS 1Y (TTM)-105.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-366.67%
Revenue 1Y (TTM)-24.38%
Revenue growth 3Y4.23%
Revenue growth 5Y1.82%
Sales Q2Q%-50.23%

3.2 Future

The Earnings Per Share is expected to grow by 19.83% on average over the next years. This is quite good.
AQST is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.98% yearly.
EPS Next Y-39.27%
EPS Next 2Y-6.66%
EPS Next 3Y15.21%
EPS Next 5Y19.83%
Revenue Next Year-23.59%
Revenue Next 2Y2.95%
Revenue Next 3Y17.91%
Revenue Next 5Y31.98%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AQST Yearly Revenue VS EstimatesAQST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
AQST Yearly EPS VS EstimatesAQST Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AQST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AQST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AQST Price Earnings VS Forward Price EarningsAQST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AQST Per share dataAQST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

AQST's earnings are expected to grow with 15.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.66%
EPS Next 3Y15.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AQST!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AQUESTIVE THERAPEUTICS INC

NASDAQ:AQST (8/26/2025, 8:15:13 PM)

After market: 3.8703 -0.03 (-0.76%)

3.9

+0.04 (+1.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-03 2025-11-03/amc
Inst Owners43.84%
Inst Owner Change7.87%
Ins Owners5.65%
Ins Owner Change13.44%
Market Cap470.34M
Analysts84
Price Target8.59 (120.26%)
Short Float %8.52%
Short Ratio7.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9.97%
Min EPS beat(2)-38.41%
Max EPS beat(2)18.46%
EPS beat(4)1
Avg EPS beat(4)-14.46%
Min EPS beat(4)-38.41%
Max EPS beat(4)18.46%
EPS beat(8)3
Avg EPS beat(8)-5.6%
EPS beat(12)7
Avg EPS beat(12)3.33%
EPS beat(16)11
Avg EPS beat(16)6.54%
Revenue beat(2)0
Avg Revenue beat(2)-21.73%
Min Revenue beat(2)-30.1%
Max Revenue beat(2)-13.36%
Revenue beat(4)1
Avg Revenue beat(4)-14.54%
Min Revenue beat(4)-30.1%
Max Revenue beat(4)4.68%
Revenue beat(8)2
Avg Revenue beat(8)-1.6%
Revenue beat(12)6
Avg Revenue beat(12)1.44%
Revenue beat(16)10
Avg Revenue beat(16)5.85%
PT rev (1m)0%
PT rev (3m)-14.65%
EPS NQ rev (1m)-3.16%
EPS NQ rev (3m)-13.95%
EPS NY rev (1m)1.84%
EPS NY rev (3m)-2.16%
Revenue NQ rev (1m)3.21%
Revenue NQ rev (3m)-6.31%
Revenue NY rev (1m)-0.4%
Revenue NY rev (3m)-2.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.66
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.7
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS0.37
BVpS-0.6
TBVpS-0.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.42%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.09%
FCFM N/A
ROA(3y)-50.85%
ROA(5y)-71.01%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y2.38%
F-Score1
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 57.61%
Cap/Sales 0.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.53
Quick Ratio 3.18
Altman-Z -4.91
F-Score1
WACC10.78%
ROIC/WACCN/A
Cap/Depr(3y)67.19%
Cap/Depr(5y)49.48%
Cap/Sales(3y)2.51%
Cap/Sales(5y)2.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-105.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-366.67%
EPS Next Y-39.27%
EPS Next 2Y-6.66%
EPS Next 3Y15.21%
EPS Next 5Y19.83%
Revenue 1Y (TTM)-24.38%
Revenue growth 3Y4.23%
Revenue growth 5Y1.82%
Sales Q2Q%-50.23%
Revenue Next Year-23.59%
Revenue Next 2Y2.95%
Revenue Next 3Y17.91%
Revenue Next 5Y31.98%
EBIT growth 1Y-246.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-91.94%
EBIT Next 3Y28.93%
EBIT Next 5Y37.98%
FCF growth 1Y-621.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-508.58%
OCF growth 3YN/A
OCF growth 5YN/A